Literature DB >> 21371186

Application of UKHCDO 2004 guidelines in type 1 von Willebrand Disease--a single centre paediatric experience of the implications of altered or removed diagnosis.

T Dutt1, S Burns, N Mackett, C Benfield, R Lwin, R Keenan.   

Abstract

Diagnosis of type I von Willebrand Disease (VWD) can be challenging. In 2004, the United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) proposed more stringent diagnostic criteria to replace the 1995 guidelines. To determine the true number of cases of type 1 VWD in a single paediatric centre, the 2004 UKHCDO Guideline for the diagnosis of VWD was used to evaluate 114 patients on our type 1 VWD register. Clinical and laboratory data were collected and analysed to see whether they met the criteria for type 1 VWD. Only 8% remained on the type 1 VWD register. 18% have been classified as 'possible type 1 VWD'. Twenty five surgical procedures have since been performed on patients from the group in which the diagnosis was removed without any haemostatic support or bleeding complications. Reaction to the removal of the VWD diagnosis or delivery of an alternative diagnosis was positive for most patients and families. This study is the first to assess the impact of the 2004 UKHCDO Guidelines on the diagnosis of VWD. It provides evidence that the prevalence of type 1 VWD may actually be closer to that of haemophilia instead of the previously reported 1-3% of the general population. We propose that all centres should review their patients with a diagnosis of VWD to revalidate this disease that claims to be our most common inherited bleeding disorder.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371186     DOI: 10.1111/j.1365-2516.2010.02452.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  2 in total

1.  Guidelines for the genetic diagnosis of hereditary recurrent fevers.

Authors:  Y Shinar; L Obici; I Aksentijevich; B Bennetts; F Austrup; I Ceccherini; J M Costa; A De Leener; M Gattorno; U Kania; I Kone-Paut; S Lezer; A Livneh; I Moix; R Nishikomori; S Ozen; L Phylactou; L Risom; D Rowczenio; T Sarkisian; M E van Gijn; M Witsch-Baumgartner; M Morris; H M Hoffman; I Touitou
Journal:  Ann Rheum Dis       Date:  2012-06-01       Impact factor: 19.103

Review 2.  Current therapy in children and adolescents with von Willebrand disease.

Authors:  I Buga-Corbu; C Arion
Journal:  J Med Life       Date:  2014-06-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.